Cancers 2010, 2(4), 2044-2054; doi:10.3390/cancers2042044
Review

Human Equilibrative Nucleoside Transporter 1 (hENT1) in Pancreatic Adenocarcinoma: Towards Individualized Treatment Decisions

Department of Medicine, Cross Cancer Institute, University of Alberta, 11560 University Avenue, Edmonton, Alberta T6G 1Z2, Canada
* Author to whom correspondence should be addressed.
Received: 22 October 2010; in revised form: 29 November 2010 / Accepted: 30 November 2010 / Published: 2 December 2010
(This article belongs to the Special Issue Pancreatic Cancer)
PDF Full-text Download PDF Full-Text [141 KB, Updated Version, uploaded 3 December 2010 10:07 CET]
The original version is still available [141 KB, uploaded 2 December 2010 18:16 CET]
Abstract: Pancreatic cancer is one of the most lethal cancers, where curative surgical resections are rare and less than 5% of patients experience long-term survival. Despite numerous clinical trials, improvements in the systemic treatment of this disease have been limited. Gemcitabine, a nucleoside analogue, is still considered the standard of care chemotherapy for most patients in the advanced disease setting. To exert its cytotoxic effects, gemcitabine must enter cells via nucleoside transporters, most notably human equilibrative nucleoside transporter 1 (hENT1). Increasingly strong evidence suggests hENT1 is a prognostic biomarker in gemcitabine-treated pancreatic cancer, and may well be a predictive biomarker of gemcitabine efficacy. In this review, we synthesize the literature surrounding hENT1 in pancreatic cancer, identify the key outstanding questions, and suggest strategies to prospectively evaluate the clinical utility of hENT1 in future clinical studies.
Keywords: nucleoside transporters; hENT1; pancreatic adenocarcinoma; predictive tool; individualized medicine

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Spratlin, J.L.; Mackey, J.R. Human Equilibrative Nucleoside Transporter 1 (hENT1) in Pancreatic Adenocarcinoma: Towards Individualized Treatment Decisions. Cancers 2010, 2, 2044-2054.

AMA Style

Spratlin JL, Mackey JR. Human Equilibrative Nucleoside Transporter 1 (hENT1) in Pancreatic Adenocarcinoma: Towards Individualized Treatment Decisions. Cancers. 2010; 2(4):2044-2054.

Chicago/Turabian Style

Spratlin, Jennifer L.; Mackey, John R. 2010. "Human Equilibrative Nucleoside Transporter 1 (hENT1) in Pancreatic Adenocarcinoma: Towards Individualized Treatment Decisions." Cancers 2, no. 4: 2044-2054.

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert